EPHB4 and survival of colorectal cancer patients

被引:70
作者
Davalos, Veronica
Dopeso, Higinio
Castano, Julio
Wilson, Andrew J.
Vilardell, Felip
Romero-Gimenez, Jordi
Espin, Eloy
Armengol, Manel
Capella, Gabriel
Mariadason, John M.
Aaltonen, Lauri A.
Schwartz, Simo, Jr.
Arango, Diego
机构
[1] Hosp Gen Valle Hebron, Res Inst, Funct Gen Program, Mol Onocl & Aging Grp,Mol Biol & Biochem Res Ctr, Barcelona 08035, Spain
[2] Hosp Gen Valle Hebron, Res Inst, Mol Oncol Program, Mol Onocl & Aging Grp,Mol Biol & Biochem Res Ctr, Barcelona 08035, Spain
[3] Inst Catala Oncol, Translat Res Lab, Barcelona, Spain
[4] Albert Einstein Canc Ctr, Montefiore Med Ctr, Bronx, NY USA
[5] Univ Helsinki, Dept Med Genet, Helsinki, Finland
关键词
D O I
10.1158/0008-5472.CAN-05-4640
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The family of receptor tyrosine kinases EPH and their Ephrin ligands regulate cell proliferation, migration, and attachment. An important role in colorectal carcinogenesis is emerging for some of its members. In this study, we evaluate the role of EPHB4 in colorectal cancer and its value as a prognostic marker. EPHB4 levels were assessed by immunohistochemical staining of tissue microarrays of 137 colorectal tumors and aberrant hypermethylation of the EPHB4 promoter was investigated using methylation-specific PCR. We found that EPHB4 expression is frequently reduced or lost in colorectal tumors. Patients with low EPHB4 tumor levels had significantly shorter survival than patients in the high EPHB4 group (median survival, 1.8 and > 9 years, respectively; P < 0.01, logrank test), and this finding was validated using an independent set of 125 tumor samples. In addition, we show that EPHB4 promoter hypermethylation is a common mechanism of EPHB4 inactivation. Moreover, reintroduction of EPHB4 resulted in a significant reduction in the clonogenic potential of EPHB4-deficient cells, whereas abrogation of EPHB4 in cells with high levels of this receptor lead to a significant increase in clonogenicity. In summary, we identified EPHB4 as a useful prognostic marker for colorectal cancer. In addition, we provide mechanistic evidence showing that promoter methylation regulates EPHB4 transcription and functional evidence that EPHB4 can regulate the long-term clonogenic potential of colorectal tumor cells, revealing EPHB4 as a potential new tumor suppressor gene in colorectal cancer.
引用
收藏
页码:8943 / 8948
页数:6
相关论文
共 25 条
[1]   Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors [J].
Alazzouzi, H ;
Davalos, V ;
Kokko, A ;
Domingo, E ;
Woerner, SM ;
Wilson, AJ ;
Konrad, L ;
Laiho, P ;
Espín, E ;
Armengol, M ;
Imai, K ;
Yamamoto, H ;
Mariadason, JM ;
Gebert, JF ;
Aaltonen, LA ;
Schwartz, S ;
Arango, D .
CANCER RESEARCH, 2005, 65 (22) :10170-10173
[2]   SMAD4 as a prognostic marker in colorectal cancer [J].
Alazzouzi, H ;
Alhopuro, P ;
Salovaara, R ;
Sammalkorpi, H ;
Järvinen, H ;
Mecklin, JP ;
Hemminki, A ;
Schwartz, S ;
Aaltonen, LA ;
Arango, D .
CLINICAL CANCER RESEARCH, 2005, 11 (07) :2606-2611
[3]   Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer [J].
Arango, D ;
Laiho, P ;
Kokko, A ;
Alhopuro, P ;
Sammalkorpi, H ;
Salovaara, R ;
Nicorici, D ;
Hautaniemi, S ;
Alazzouzi, H ;
Salovaara, R ;
Nicorici, D ;
Hautaniemi, S ;
Alazzouzi, H ;
Mecklin, JP ;
Järvinen, H ;
Hemminki, A ;
Astola, J ;
Schwartz, S ;
Aaltonen, LA .
GASTROENTEROLOGY, 2005, 129 (03) :874-884
[4]   c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis [J].
Arango, D ;
Mariadason, JM ;
Wilson, AJ ;
Yang, W ;
Corner, GA ;
Nicholas, C ;
Aranes, MJ ;
Augenlicht, LH .
BRITISH JOURNAL OF CANCER, 2003, 89 (09) :1757-1765
[5]   EphB receptor activity suppresses colorectal cancer progression [J].
Batlle, E ;
Bacani, J ;
Begthel, H ;
Jonkeer, S ;
Gregorieff, A ;
van de Born, M ;
Malats, N ;
Sancho, E ;
Boon, E ;
Pawson, T ;
Gallinger, S ;
Pals, S ;
Clevers, H .
NATURE, 2005, 435 (7045) :1126-1130
[6]   β-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/EphrinB [J].
Batlle, E ;
Henderson, JT ;
Beghtel, H ;
van den Born, MMW ;
Sancho, E ;
Huls, G ;
Meeldijk, J ;
Robertson, J ;
van de Wetering, M ;
Pawson, T ;
Clevers, H .
CELL, 2002, 111 (02) :251-263
[7]   Expression of the receptor protein tyrosine kinase myk-1/htk in normal and malignant mammary epithelium [J].
Berclaz, G ;
Andres, AC ;
Albrecht, D ;
Dreher, E ;
Ziemiecki, A ;
Gusterson, BA ;
Crompton, MR .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 226 (03) :869-875
[8]   Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma [J].
Berclaz, G ;
Karamitopoulou, E ;
Mazzucchelli, L ;
Rohrbach, V ;
Dreher, E ;
Ziemiecki, A ;
Andres, AC .
ANNALS OF ONCOLOGY, 2003, 14 (02) :220-226
[9]   Epigenetics in human disease and prospects for epigenetic therapy [J].
Egger, G ;
Liang, GN ;
Aparicio, A ;
Jones, PA .
NATURE, 2004, 429 (6990) :457-463
[10]   Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development [J].
Gerety, SS ;
Wang, HU ;
Chen, ZF ;
Anderson, DJ .
MOLECULAR CELL, 1999, 4 (03) :403-414